Merck 1Q09 1Q Revenues: $5.4 billion (-8%) 1Q Earnings: $1.4 billion (-57%) Comments: Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%). Sales of Cozaar and Hyzaar2 were $839 million (-1%). Januvia sales were $411 million (+51%). Sales of Fosamax and Fosamax Plus D dropped 44% to $261 million due to loss of U.S. marketing exclusivity. Restructuring costs, prima...